Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Neoadjuvant Chemotherapy Followed by Gastrectomy for Cytology-Positive Gastric Cancer without Any Other Non-Curative Factors in a Western Setting: An International Eastern European Cohort Study.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Bausys, Augustinas; Ümarik, Toomas; Dobrzhanskyi, Oleksii; Luksta, Martynas; Kondratskyi, Yourii; Reinsoo, Arvo; Vassiljev, Mihhail; Bausys, Bernardas; Bickaite, Klaudija; Rauduvyte, Kornelija; Luksaite-Lukste, Raminta; Bausys, Rimantas; Strupas, Kestutis
- المصدر:
Cancers; Dec2023, Vol. 15 Issue 24, p5794, 13p
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
Simple Summary: This multicenter study delved into the outcomes of treating stage IV gastric cancer patients with positive peritoneal cytology but no other non-curative factors using chemotherapy followed by gastrectomy. The findings revealed that preoperative chemotherapy successfully eliminated peritoneal cancer cells in over 50% of patients. The median Overall and Progression-free survival stood at 20 (95% CI: 16–25) and 19 (95% CI: 11–20) months, respectively. Notably, conversion to negative cytology significantly lowered the relative risk of peritoneal progression (RR: 0.11; 95% CI: 0.03–0.47, p = 0.002). This study proposes that preoperative chemotherapy followed by gastrectomy shows promise as a viable treatment for stage IV gastric cancer patients with positive peritoneal cytology and no additional non-curative factors. The conversion of cytology status is associated with enhanced long-term outcomes and diminished risk of peritoneal relapse. The optimal approach for treating cytology-positive (Cy1) gastric cancer (GC) patients without additional non-curative factors remains uncertain. While neoadjuvant chemotherapy followed by gastrectomy shows promise, its suitability for Western patients is not well supported by existing data. To address this knowledge gap, a cohort study was conducted across four major GC treatment centers in Lithuania, Estonia, and Ukraine. Forty-three consecutive Cy1 GC patients who underwent neoadjuvant chemotherapy between 2016 and 2020 were enrolled. The study evaluated overall survival (OS), progression-free survival (PFS), cytology status conversion, and major pathological response rates, along with the factors influencing these outcomes. All patients underwent surgery post-neoadjuvant chemotherapy, with 53.5% experiencing cytological status conversion and 23.3% achieving a major pathological response. The median OS and PFS were 20 (95% CI: 16–25) and 19 (95% CI: 11–20) months, respectively. Conversion to negative cytology significantly reduced the relative risk of peritoneal progression (RR: 0.11; 95% CI: 0.03–0.47, p = 0.002). The study suggests that neoadjuvant chemotherapy followed by gastrectomy holds promise as a treatment option for Cy1 GC without additional non-curative factors, associating cytology status conversion with improved long-term outcomes and reduced peritoneal relapse risk. [ABSTRACT FROM AUTHOR]
- نبذة مختصرة :
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.